Dr Malinda Itchins
/content/dam/genesiscare/headshots/au-doctor-headshots/AU_Medical oncology_Headshot_GA_Dr Malinda Itchins.jpg

Dr Malinda Itchins

Dr Malinda Itchins
BMedSci, MBBS (Hons1), FRACP, PhD, Medical Oncologist

Looking after people at the most vulnerable time in their lives whilst navigating a cancer diagnosis is a privilege.

Languages spoken




North Shore
North Shore
-33.82024297423824, 151.19062046149045

Clinical interests in treating lung/thoracic cancers, and gastrointestinal (GI) cancers including pancreatic.

Malinda is originally from a small town in Tasmania and completed her undergraduate medical degree through UTas in 2009. She worked at the Royal Hobart Hospital before moving to Sydney in 2012 to begin specialist training at Royal North Shore Hospital.

Malinda was admitted as a Fellow of the Royal Australasian College of Physicians in 2016 in Medical Oncology, and thereafter in 2020 awarded the degree of Doctor of Philosophy through USyd for her bedside to bench top research into lung cancers. She was the recipient of the Inaugural NSW Health PhD Scholarship 2017-2020. During her doctoral studies she worked part-time as a Staff Specialist Medical Oncologist and Locum Oncologist at Royal North Shore and North Shore Private Hospitals, and the Northern Cancer Institute (now GenesisCare).

Malinda is passionate about multidisciplinary comprehensive cancer care, optimising an efficient cancer diagnosis, patient advocacy, streamlining care including clinical trial inclusion, and undertaking research to continue improving patient outcomes.

Malinda has been recognised with the Pfizer ANZ Clinical Trial Medical Grant 2017-2022, Fight for a Cure Translational Research Grant 2019, and was the Sydney Vital Research Scholar Awards 2018, 2019.

When not at work, Malinda and her husband spend time with their young daughter and their chihuahua and she enjoys exercise with long distance running and de-stressing with cross training in the gym.

She is a great supporter of the positive impact and evidence for exercise in all avenues of cancer care and wellness.

Research interests

  • Understanding mechanisms of, and strategies to prevent drug resistance in cancer.
  • Studying the multidisciplinary team treatment approach in lung and pancreatic cancer.

Professional memberships

  • Thoracic Oncology Group of Australasia (TOGA)- Early Career Representative, Scientific Committee
  • Clinical Oncology Society of Australia (COSA)- Lung Cancer Chair
  • International Association for the Study of Lung Cancer (IASLC) Member
  • Australasian Gastrointestinal Trials Group (AGITG) Member


  • Itchins M et al. Precision Medicine Clinic: Molecular Tumor Board ALK-rearranged non-small cell lung cancer in 2020: Real-world triumphs in an era of multi-generation ALK-inhibitor sequencing informed by drug resistance profiling. The Oncologist. 2020;25(8)641-649
  • Alexander M… Itchins M. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer. 2020;142:34-40
  • Itchins M et al. Pattern of Care and Survival of Anaplastic Lymphoma Kinase Rearranged Non-Small Cell Lung Cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre. A Retrospective Cohort Analysis. Asia Pac J Clin Oncol. 2018;14(5):e275-82
  • Itchins M et al. Treatment of ALK-rearranged non-small cell lung cancer – a review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia Pac J Clin Oncol. 2017; 13:3-13
  • Itchins M et al. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre. Eur J Surg Oncol. 2017; 43(9):1711-7